AM095

AM095

Catalog Number:
L002368513APE
Mfr. No.:
APE-A3166
Price:
$284
  • Size:
    Quantity:
    Add to Cart:
      • Overview
        • Please contact us at for specific academic pricing.

          Background

          AM095 is a novel, potent and orally bioavailable antagonist of lysophosphatidic acid type 1 receptor (LPA1) with IC50 values of 0.73 and 0.98 μM for mouse or recombinant human LPA1, respectively [1].
          In vitro, AM095 has shown to inhibit LPA1-induced chemotaxis of both mouse LPA1/CHO cells and human A2058 melanoma cells with IC50 values of 0.78 μM and 0.23μM [1].
          In vivo, AM095 could dose-dependently block LPA-induced histamine release with an ED50 value of 8.3 mg/kg in mice. Additionally, AM095 has been revealed to remarkably reduce the BALF collagen and protein with an ED50 value of 10 mg/kg in lungs. AM095 has also shown to decrease both macrophage and lymphocyte infiltration induced by bleomycin in mice [1].

          [1] Swaney JS1, Chapman C, Correa LD, Stebbins KJ, Broadhead AR, Bain G, Santini AM, Darlington J, King CD, Baccei CS, Lee C, Parr TA, Roppe JR, Seiders TJ, Ziff J, Prasit P, Hutchinson JH, Evans JF, Lorrain DS. Pharmacokinetic and pharmacodynamic characterization of an oral lysophosphatidic acid type 1 receptor-selective antagonist. J Pharmacol Exp Ther. 2011 Mar;336(3):693-700.

      • Properties
        • Categories
          Potent LPA1 receptor antagonist
          Alternative Name
          AM 095;AM-095; sodium;2-[4-[4-[3-methyl-4-[[(1R)-1-phenylethoxy]carbonylamino]-1,2-oxazol-5-yl]phenyl]phenyl]acetate
          CAS Number
          1345614-59-6
          Molecular Formula
          C27H23N2NaO5
          Molecular Weight
          478.47
          Appearance
          A solid
          Purity
          99.66%
          Solubility
          ≥23.9 mg/mL in DMSO; insoluble in H2O; ≥16.77 mg/mL in EtOH with ultrasonic
          Storage
          Store at -20°C
          SMILES
          CC1=NOC(=C1NC(=O)OC(C)C2=CC=CC=C2)C3=CC=C(C=C3)C4=CC=C(C=C4)CC(=O)[O-].[Na+]

          * For Research Use Only

      • Reference
        • 1. Ingrid Lua, Steven Balog, et al. "Loss of lysophosphatidic acid receptor 1 in hepatocytes reduces steatosis via down-regulation of CD36." Prostaglandins Other Lipid Mediat. 2021 Oct;156:106577. PMID:34147666
          2. Harper K, R Lavoie R, et al. "The Hypoxic Tumor Microenvironment Promotes Invadopodia Formation and Metastasis through LPA1 Receptor and EGFR Cooperation." Mol Cancer Res. 2018 Jun 4. pii:molcanres.0649.2017. PMID:29866927
          3. Szepanowski F, Szepanowski LP, et al. "Lysophosphatidic acid propagates post-injury Schwann cell dedifferentiation through LPA(1) signaling. Neurosci Lett." 2017 Oct 16;662:136-141. PMID:29051083
          4. Banks DB, Chan GN, et al. "Lysophosphatidic acid and amitriptyline signal through LPA1R to reduce P-glycoprotein transport at the blood-brain barrier." J Cereb Blood Flow Metab. 2018 May;38(5):857-868. PMID:28447863

    We Also Recommend

    AM679

    $490

    Note: If you don't receive our verification email, do the following:

    Copyright © Amerigo Scientific. All rights reserved.